MergerLinks - David R. Bauer

MergerPublic

target

Oncomed Pharmaceuticals

bidder

Mereo Biopharma Group

£45m

27 dealmakers

PublicMergerAcquisitionMajority

target

Spark Therapeutics

bidder

Roche Holdings

£3,291m

29 dealmakers

PrivateAcquisitionMajority

target

Promedior

bidder

Roche Holdings

£1,078m

11 dealmakers

AcquisitionMajorityPublicDomestic

Medical Supplies

target

Hemacare Corporation

bidder

Charles River Laboratories International

£252m

25 dealmakers

AcquisitionPrivatePrivate EquityMajorityCross Border

Medical Services

target

Corvidia Therapeutics

bidder

Novo Nordisk

£1,646m

55 dealmakers

AcquisitionPrivateMajorityPrivate EquityDomestic

Management Consulting

target

Water Street Partners

bidder

Ankura Consulting Group

value n/a

29 dealmakers

AcquisitionMajorityPrivateCross BorderPrivate Equity

target

FORBIUS

bidder

Bristol Myers Squibb Company

value n/a

49 dealmakers

MajorityDomesticPublicAcquisitionTender Offer

target

IMMUNOMEDICS

bidder

Gilead Sciences

£16,407m

50 dealmakers

Cross BorderPrivateAcquisitionMajorityPrivate Equity

Software

target

Kindred Systems

bidder

Ocado Group

£222m

27 dealmakers

MajorityAcquisitionCross BorderPrivate

target

Nine Continents Medical

bidder

COLOPLAST

£112m

16 dealmakers

Cross BorderPrivateMajorityAcquisition

target

Emisphere Technologies

bidder

Novo Nordisk

£1,027m

34 dealmakers

PrivateAcquisitionDomesticMajorityPrivate Equity

target

Cognate Bioservices

bidder

Charles River Laboratories International

£628m

40 dealmakers

PrivateDomesticMajorityAcquisition

target

Mdlive

bidder

EVERNORTH

£1,416m

20 dealmakers

Farming Fishing Ranching and Plantations

AcquisitionPrivateCross BorderMajorityPrivate Equity

target

Sun World International

bidder

Bridgepoint Group

value n/a

12 dealmakers

Switzerland

Cross BorderMajorityDe-SPACReverse TakeoverPrivate EquityMergerPrivateAcquisition

target

Roivant Sciences

bidder

Montes Archimedes Acquisition Corp

£5,280m

39 dealmakers

De-SPACMajorityDomesticAcquisitionReverse TakeoverPrivate

Digital Services

target

AGILETHOUGHT

bidder

Liv Capital Acquisition Corp

£344m

36 dealmakers

United StatesChina

MajorityAcquisitionDomesticPrivatePrivate Equity

target

Vigene Biosciences

bidder

Charles River Laboratories International

£248m

32 dealmakers

AcquisitionPrivateMinorityCross BorderPrivate EquityVenture Capital

Payments / Commerce

target

TBCASOFT

bidder

Naver Corporation

£17m

12 dealmakers

AcquisitionDomesticPrivateMajority

Management Consulting

target

Mclarty Associates

bidder

Ankura Consulting Group

value n/a

14 dealmakers

MajorityCross BorderAcquisitionPublic

target

DICERNA

bidder

Novo Nordisk

£2,452m

23 dealmakers

Private EquityDe-SPACDomesticMajorityAcquisitionMergerPrivateReverse Takeover

target

Senti Biosciences

bidder

Dynamics Special Purpose Corporation

£453m

42 dealmakers

PrivateCross BorderAcquisitionMajority

target

Engage Surgical

bidder

Smith & Nephew

£99m

14 dealmakers

Information / Data Services

MajorityDomesticAcquisitionPrivate

target

Noragh Analytics

bidder

Ankura Consulting Group

value n/a

14 dealmakers

MinorityVenture CapitalPrivateDomesticPrivate EquityAcquisition

Food Products

target

The Honest Kitchen

bidder

Monarch Alternative Capital

£114m

12 dealmakers

MajorityAcquisitionDomesticPrivate

target

Explora Biolabs

bidder

Charles River Laboratories International

£224m

15 dealmakers

PrivatisationCross BorderPublicAcquisitionPrivate EquityMajority

Medical Equipment

target

Natus Medical

bidder

Archimed

£919m

28 dealmakers

MajorityPrivateDomesticAcquisition

target

Acutus Medical (left-heart Access Portfolio)

bidder

Medtronic

£39m

14 dealmakers

PrivateCross BorderAcquisitionMajority

target

Affinivax

bidder

Glaxosmithkline

£2,610m

27 dealmakers

MajorityPrivateAcquisitionDomestic

target

Trans Ova Genetics

bidder

URUS

£148m

21 dealmakers

United Kingdom

MajorityCross BorderPrivateAcquisitionPrivate Equity

target

MIROBIO

bidder

Gilead Sciences

£333m

42 dealmakers

PrivateDomesticPrivate EquityMajorityAcquisition

Plastics

target

Molded Devices

bidder

Truarc Partners

value n/a

17 dealmakers

AcquisitionPublicCross BorderMajority

target

Forma Therapeutics

bidder

Novo Nordisk

£944m

65 dealmakers

Switzerland

Reverse TakeoverMajorityMergerAcquisitionPrivateDe-SPACPrivate EquityCross Border

target

OCULIS

bidder

Tekla Capital Management

£194m

25 dealmakers

CanadaChina

Plastics

PrivateAcquisitionMajorityPrivate EquityCross Border

target

SCHAUENBURG‐TRUPLAST

bidder

Molded Devices

value n/a

27 dealmakers

AcquisitionPrivateMinorityPrivate EquityDomestic

target

MORGENESIS

bidder

Metalmark Capital

£43m

13 dealmakers

MajorityPublicAcquisitionCross Border

target

Concert Pharmaceuticals

bidder

Sun Pharmaceutical Industries

£346m

55 dealmakers

Financial Data and Systems

AcquisitionDomesticMajorityPrivate

target

Chartwell Compliance

bidder

Ankura Consulting Group

value n/a

25 dealmakers

Canada

AcquisitionDe-SPACCross BorderMergerPrivateVenture CapitalMajorityReverse Takeover

target

Engene

bidder

Forbion European Acquisition Corp

£196m

19 dealmakers

Sweden

AcquisitionCross BorderPrivateMajority

target

Nda Group

bidder

Ssi Strategy

value n/a

15 dealmakers

AcquisitionMajorityPrivateDomestic

Semiconductors

target

His Innovations Group

bidder

Ultra Clean Holdings

£82m

11 dealmakers

Israel

Medical Equipment

AcquisitionPrivateCross BorderMajority

target

CARTIHEAL

bidder

Smith & Nephew

£263m

17 dealmakers

United Kingdom

Medical Equipment

AcquisitionMajorityCross BorderPrivate

target

Lumiradx (point Of Care Technology Platform)

bidder

Roche Holdings

£273m

12 dealmakers

DomesticPrivateAcquisitionMinorityPrivate Equity

Auto Technology

target

Humanetics Group

bidder

ANSYS

value n/a

13 dealmakers

AcquisitionDomesticMajorityPrivate

Management Consulting

target

LUMERI

bidder

Ankura Consulting Group

value n/a

11 dealmakers

ItalyBelgium

Cross BorderAcquisitionInfrastructureMajorityPrivatePrivate Equity

target

Novo Holdings (three Fill-finish Sites)

bidder

Novo Nordisk

£8,704m

29 dealmakers

AcquisitionDomesticMajorityPublic

target

Cymabay Therapeutics

bidder

Gilead Sciences

£3,404m

30 dealmakers

AcquisitionDomesticMajorityPrivate EquityPrivate

Specialty Chemicals

target

Meyer Lab

bidder

Truarc Partners

value n/a

23 dealmakers

United StatesUnited States